Preface
1. INFLAMMATION AND PNEUMONIA: WHY ARE SOME MORE SUSCEPTIBLE THAN OTHERS?
2. THE LUNG MICROBIOME AND ITS ROLE IN PNEUMONIA
3. BIOMARKERS FOR THE MANAGEMENT OF PNEUMONIA
4. NFLUENZA AND VIRAL PNEUMONIA
5. Guidelines to Manage Community-Acquired Pneumonia
6. Vaccines to Prevent Community-Acquired Pneumonia
7. Adjunctive Therapies for Community-Acquired Pneumonia
8. HEALTHCARE ASSOCIATED PNEUMONIA: STILL A USEFUL CONCEPT?
9. AIRWAY DEVICES IN VAP PATHOGENESIS AND PREVENTION
10. MANAGEMENT OF VAP: GUIDELINES
11. HOW CAN WE DISTINGUISH VENTILATOR ASSOCIATED TRACHEOBRONCHITIS FROM VAP?
12. IS ZERO VAP ACHIEVABLE? PRACTICAL APPROACHES TO VAP PREVENTION
13. AEROSOL THERAPY OF PNEUMONIA IN THE ICU
14. Optimizing Antibiotic Administration for Pneumonia
15. New Antibiotics for Pneumonia
16. PERSONALIZED APPROACH TO PNEUMONIA MANAGEMENT
